Evidence map›Paper›PMID 39965056›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Engineered Nanocatalyst-Enabled Cheolesterol Depletion for Enhanced Tumor Piezocatalytic Therapy.

Mengdan Li, Yajun Zhou, Xiaoyang Chen, Weiwei Chen, Yifei Yang, Cheng Qian, Lei Yang, Yaohan Zhang, Zheng Zhang, Wencheng Wu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mengdan LiDepartment of Medical Ultrasound, Affiliated Hospital of Nantong University, Medical School of NanTong University, Nantong, Jiangsu, 226001, P. R. China.
Yajun ZhouDepartment of Ultrasound, The Fourth Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210029, P. R. China.
Xiaoyang ChenDepartment of Medical Ultrasound, Affiliated Hospital of Nantong University, Medical School of NanTong University, Nantong, Jiangsu, 226001, P. R. China.
Weiwei ChenDepartment of Medical Ultrasound, Affiliated Hospital of Nantong University, Medical School of NanTong University, Nantong, Jiangsu, 226001, P. R. China.
Yifei YangDepartment of Medical Ultrasound, Affiliated Hospital of Nantong University, Medical School of NanTong University, Nantong, Jiangsu, 226001, P. R. China.
Cheng QianDepartment of Medical Ultrasound, Affiliated Hospital of Nantong University, Medical School of NanTong University, Nantong, Jiangsu, 226001, P. R. China.
Lei YangDepartment of Medical Ultrasound, Affiliated Hospital of Nantong University, Medical School of NanTong University, Nantong, Jiangsu, 226001, P. R. China.
Yaohan ZhangDepartment of Medical Ultrasound, Affiliated Hospital of Nantong University, Medical School of NanTong University, Nantong, Jiangsu, 226001, P. R. China.
Zheng ZhangDepartment of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, 212000, P. R. China.
Wencheng WuCentral Laboratory and Department of Medical Ultrasound, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610072, P. R. China.ORCID https://orcid.org/0009-0002-8850-2162
Yifei YinDepartment of Medical Ultrasound, Affiliated Hospital of Nantong University, Medical School of NanTong University, Nantong, Jiangsu, 226001, P. R. China.

Funding

Medical research project of Jiangsu Provincial Health Commission H2023141Nantong Natural Science Foundation JCZ2023028National Natural Science Foundation of China 52402353National Science Foundation for Young Scientists of China 82302208Postdoctoral Science Foundation 2022M711721Sichuan Province Science and Technology Program 2025ZNSFSC0237
6 · The paper itself

Abstract

The inadequate generation of reactive oxygen species (ROS) and metastasis of malignant tumors are critical factors that limit the efficacy of conventional sonodynamic therapy in cancer treatment. Herein, an engineered piezocatalyst: cholesterol oxidase (CHO)-loaded Pt-ZnO nanoparticles (Pt-ZnO/CHO) that can explosively generate large amounts of ROS and block the metastasis of tumor, is developed for improving piezocatalytic tumor therapy. In this process, Pt-ZnO can substantially generate ROS via initiating ultrasound (US)-triggered piezocatalytic reactions. In situ-grown Pt nanoparticles not only optimize piezocatalytic activities but also facilitate oxygen (O

Indexed as

CholesterolCholesterol OxidaseNanoparticlesNeoplasmsUltrasonic TherapyAnimalsCatalysisCell Line, TumorCell ProliferationHumansMicePlatinumReactive Oxygen SpeciesZinc OxideCholesterolCholesterol OxidasePlatinumReactive Oxygen SpeciesZinc Oxidecholesterol depletionpiezocatalytic tumor therapyreactive oxygen speciestumor antimetastatic

Identifiers

PMID39965056
PMCPMC11984833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.